SG11202108810YA - Use of vibegron to treat overactive bladder - Google Patents

Use of vibegron to treat overactive bladder

Info

Publication number
SG11202108810YA
SG11202108810YA SG11202108810YA SG11202108810YA SG 11202108810Y A SG11202108810Y A SG 11202108810YA SG 11202108810Y A SG11202108810Y A SG 11202108810YA SG 11202108810Y A SG11202108810Y A SG 11202108810YA
Authority
SG
Singapore
Prior art keywords
vibegron
overactive bladder
treat overactive
treat
bladder
Prior art date
Application number
Inventor
Mudd, Jr
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of SG11202108810YA publication Critical patent/SG11202108810YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202108810Y 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder SG11202108810YA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US201962904429P 2019-09-23 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
SG11202108810YA true SG11202108810YA (en) 2021-10-28

Family

ID=70166082

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108810Y SG11202108810YA (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Country Status (13)

Country Link
US (1) US20230027066A1 (en)
EP (1) EP3941473A1 (en)
JP (1) JP2022524576A (en)
KR (1) KR20210142004A (en)
CN (1) CN113840607A (en)
AU (1) AU2020243514A1 (en)
BR (1) BR112021017198A2 (en)
CA (1) CA3129024A1 (en)
IL (1) IL285910A (en)
MX (1) MX2021009488A (en)
SG (1) SG11202108810YA (en)
TW (1) TW202102221A (en)
WO (1) WO2020188505A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175848A1 (en) * 2021-02-16 2022-08-25 Urovant Sciences Gmbh Methods of treating heart failure with vibegron

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
ES2584427T3 (en) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Process for the preparation of beta 3 agonists and intermediate products
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
EP2968269B1 (en) 2013-03-15 2019-07-10 Merck Sharp & Dohme Corp. Process for preparing beta 3 agonists and intermediates
AU2018282105A1 (en) * 2017-06-06 2019-12-12 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder
CA3064989A1 (en) 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder

Also Published As

Publication number Publication date
KR20210142004A (en) 2021-11-23
AU2020243514A1 (en) 2021-08-26
EP3941473A1 (en) 2022-01-26
BR112021017198A2 (en) 2021-11-16
JP2022524576A (en) 2022-05-09
WO2020188505A1 (en) 2020-09-24
MX2021009488A (en) 2021-09-21
IL285910A (en) 2021-10-31
CN113840607A (en) 2021-12-24
CA3129024A1 (en) 2020-09-24
TW202102221A (en) 2021-01-16
US20230027066A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
IL271164A (en) Use of vibegron to treat overactive bladder
IL268138A (en) Combinations of cabozantinib and atezolizumab to treat cancer
IL292840A (en) Methods of treatment with myosin modulator
IL292810A (en) Therapeutic compounds and methods of use
GB201804514D0 (en) Treatment of pyroptosis
EP3294305A4 (en) Syringes and methods of using them to treat overactive bladder
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
IL274532A (en) Use of riluzole prodrugs to treat ataxias
ZA201903795B (en) Treatment of water
IL282311A (en) Use of reboxetine to treat narcolepsy
GB201804515D0 (en) Treatment of necroptosis
IL285910A (en) Use of vibegron to treat overactive bladder
EP3829582A4 (en) Methods of treating overactive bladder using trospium
IL278978A (en) Compositions and methods for treatment of psoriasis
IL276382A (en) Use of pcbp1 to treat hyperproliferative disease
GB201918879D0 (en) Treatment of chronic pain
IL283031A (en) Vibegron for the treatment of overactive bladder symptoms
ZA202105399B (en) Use of spiropidion
GB2589398B (en) Compounds and methods of use
IL281284A (en) Methods of treating psoriasis
IL268111A (en) Methods of treating pain
GB201907305D0 (en) Treatment of conditions
GB2561333B (en) Treatment of alcohol use disorder
IL290983A (en) Methods of treatment
GB201918853D0 (en) Methods of treatment